Prestige Consumer Healthcare Inc.
Financials
Valuation Metrics
Prestige Consumer Healthcare Inc.'s Market Cap is $2.20B. At end of 2025 it was $2.95B. Ranked #1955 of 3,121 in US market (top 63%), #1216 of 1,658 on NYSE (top 73%), #128 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.20B | US#1,955/3,121 Sec#128/266 |
| Revenue | $1.10B | US#1,836/3,121 Sec#50/266 |
| Net Income | $172M | US#1,364/3,121 Sec#44/266 |
| Total Assets | $4.57B | US#1,497/3,121 Sec#39/266 |
| Net Assets | $1.92B | US#1,275/3,121 Sec#39/266 |
| Employees | 600 | US#2,199/3,121 Sec#75/266 |
| Value | ||
| P/E | 12.80x | US#597/3,121 Sec#15/266 |
| P/B | 1.15x | US#534/3,121 Sec#18/266 |
| P/S | 1.99x | US#1,288/3,121 Sec#31/266 |
| EV/EBITDA | 13.36x | US#1,334/3,121 Sec#36/266 |
| FCF Yield | 10.69% | US#510/3,121 Sec#16/266 |
| Profitability | ||
| ROE | 8.97% | US#1,485/3,121 Sec#50/266 |
| ROA | 3.77% | US#1,272/3,121 Sec#56/266 |
| Op. Margin | 26.26% | US#651/3,121 Sec#30/266 |
| Revenue Growth | -1.36% | US#2,333/3,121 Sec#137/266 |
| Earnings Growth | -19.24% | US#1,546/3,121 Sec#40/266 |
| Financial Health | ||
| Debt Ratio | 138.35% | US#1,416/3,121 Sec#184/266 |
| Total Debt | $2.06B | US#1,157/3,121 Sec#33/266 |
| FCF | $235M | US#1,305/3,121 Sec#43/266 |
| Cash | $89M | US#2,292/3,121 Sec#185/266 |
| Current Ratio | 3.23x | US#725/3,121 Sec#182/266 |
| Net Debt/EBITDA | 6.31x | US#2,183/3,121 Sec#78/266 |
| Performance | ||
| 1Y Return | -27.15% | US#2,568/3,121 Sec#221/266 |
| 1M Return | -8.07% | US#2,210/3,121 Sec#167/266 |
| From 52W High | -34.59% | US#2,283/3,121 Sec#177/266 |
| 1Y MDD | -35.28% | US#1,755/3,121 Sec#116/266 |
| Trading | ||
| Volume | 379,958 shares | US#2,247/3,121 Sec#230/266 |
| Trading Value | $18M | US#1,970/3,121 Sec#153/266 |
| Per Share | ||
| EPS | $3.63 | US#927/3,121 Sec#25/266 |
| BPS | $40.46 | US#612/3,121 Sec#11/266 |
Company Info
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.